Back to the Top


Name: Gamunex
Synonyms: Intravenous Immunoglobulin, Human Albumin Combined With Flebogamma
Therapy Type: Combination, Immunotherapy (passive) (timeline)
Target Type: Amyloid-Related (timeline), Inflammation (timeline)
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Phase 2/3)
Company: Grifols Biologicals Inc.
Approved for: Immunodeficiency, chronic inflammatory demyelinating neuropathy


This immunoglobulin preparation is used in obstetric indications to prevent and treat blood conditions related to rhesus factor incompatibility. It is one of several IVIg products being tested clinically as an Alzheimer's treatment following Phase 1 and 2 results for Baxter Healthcare's IVIg product, Gammagard™.


A multicenter Phase 2/3 trial being conducted in Spain is comparing three doses of 5 percent human albumin plus 5 percent immunoglobulin to placebo delivered intravenously in 350 people with mild to moderate Alzheimer's disease. The primary outcome is change on the ADAS-Cog after 14 months of treatment. See

Clinical Trial Timeline

  • Phase 2/3
  • Study completed / Planned end date
  • Planned end date unavailable
  • Study aborted
Sponsor Clinical Trial 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034
Grifols Biologicals Inc. NCT01561053

Last Updated: 03 Oct 2023


No Available Comments

Make a Comment

To make a comment you must login or register.


Other Citations

  1. Gammagard™

External Citations


Further Reading